ProCE Banner Activity

Interactive Treatment Decision Tool for MCL: A US Perspective

Tool

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with MCL with those of 5 renowned experts from the United States.

Released: April 03, 2025

Expiration: October 02, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Disclosure

Primary Author

Stephen M. Ansell, MD, PhD: researcher: ADC Therapeutics, Affimed, AstraZeneca, Bristol-Myers Squibb, Pfizer, Regeneron, Takeda.

Ian Flinn, MD, PhD: consultant: AbbVie, BeiGene, Genentech, Genmab, Kite, Vincerx; advisor: Vincerx; researcher (paid to institution): 2seventy bio, AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Biopath, Bristol Myers Squibb, Calibr-Skaggs Institute, Celgene, Constellation, Curis, CTI Biopharma, Epizyme, Fate Therapeutics, Forma Therapeutics, Forty Seven, Genentech, Gilead, InnoCare Pharma, IGM Biosciences, Incyte, Infinity, Janssen, Kite Pharma, Loxo, Marker Therapeutics, Merck, Millennium, MorphoSys, Myeloid Therapeutics, Novartis, Nurix, Pfizer, Pharmacyclics, Portola, Rhizen, Roche, Seattle Genetics, Step Pharma, Tessa Therapeutics, TG Therapeutics, Trillium Therapeutics, TRIPhase Research & Development, Unum Therapeutics, Verastem, Vincerx.

Brad Kahl, MD: consultant/advisor/speaker: AbbVie, ADCT, AstraZeneca, BeiGene, Bristol Myers Squibb, GlaxoSmithKline, Lilly, Merck, Pfizer, Roche/Genentech.

Tycel J. Phillips, MD: consultant/advisor/speaker: AbbVie, ADCT, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou, Genentech, Genmab, Gilead, Incyte, Ipsen, Janssen, Kite, Merck, Pharmacyclics, Regeneron, Xencor; researcher: AbbVie, Genentech, Sobi.

Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie, AstraZeneca, GenMab, Lilly.